First Line Mantle Cell Lymphoma (MCL) Treatment by RiBVD Schema in Patients Older Than 65 Years or 18 to 65 Years Old Who Can't or Refuse Receive Conditioning Regimen Followed by Autograft.

Trial Profile

First Line Mantle Cell Lymphoma (MCL) Treatment by RiBVD Schema in Patients Older Than 65 Years or 18 to 65 Years Old Who Can't or Refuse Receive Conditioning Regimen Followed by Autograft.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2016

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RIBVD
  • Most Recent Events

    • 20 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 26 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top